Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia

Recruiting now · Phase 2

Conditions studied: Acute Lymphoblastic Leukemia ALL

In brief

To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.

Key facts

Study ID

NCT06608342

Run by

Institute of Hematology & Blood Diseases Hospital, China

People needed

20

Starts

2024-06-25

Expected to finish

2028-05-30

Last updated by the study team

2024-09-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients with high-risk acute B-lymphoblastic leukemia
• Complete remission was achieved after induction chemotherapy, and autologous CD19-CAR-T was successfully prepared
• Eligible for autologous hematopoietic stem cell transplantation
• No major organ dysfunction

You may not qualify if…

• Combined with malignant tumors of other organs
• With a serious infection that is not under control
• Syphilis, AIDS, hepatitis B, hepatitis C, any one of them positive
• Patients who have had an allergic reaction to the drugs used in this study or similar drugs
• Other patients deemed unsuitable for inclusion by the investigators

Where it is running

• NO.288 Nanjing Road，Heping District，Tianjin, Tianjin, — Tianjin, Tianjin Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.